Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for CIT in Lymphoma
NCT03343847Phase 3Withdrawn
- Sponsor
- Amgen
- Start
- Jan 2018
- Primary completion
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Amgen. Planned start Jan 2018; status: withdrawn.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT03343847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343847.